New Molecule BRP May Help People Lose Weight
New Molecule BRP May Help People Lose Weight
Introduction
Researchers at Stanford Medicine found a new molecule. It is called BRP. This molecule stops hunger. It works on a part of the brain. That part is the hypothalamus. This new molecule might help people lose weight. It does not cause the bad side effects of other weight loss drugs.
Main Body
The researchers used a computer tool. The tool is called Peptide Predictor. The tool looked at 20,000 human genes. It found 2,683 possible molecules. The team tested about 100 of them. BRP was the best. It helped fat mice lose weight. The mice got injections every day. Other mice did not get the injections. Those mice gained weight. The researchers want to start human tests soon. Current weight loss drugs work like a hormone. The hormone is called GLP-1. This hormone stops hunger. But it also causes nausea, vomiting, and stomach pain. BRP works only on the hypothalamus. The hypothalamus is the hunger sensor. It does not cause the bad feeling of fullness. In animal tests, BRP helped lose fat but not muscle. Some GLP-1 drugs can cause muscle loss. Other scientists say the results are good but not final. Scientists must test BRP in humans. Obesity is a long-term problem. New drugs must be safe for many years. GLP-1 drugs also help the heart. BRP might also have other benefits. More treatment options are important. Many people have obesity.
Conclusion
BRP is a new discovery. It might help people lose weight without nausea. But we need human tests to know if it is safe and works. It will not replace current drugs. It will be another tool. Using AI to find new molecules is a new way to make drugs faster.
Vocabulary Learning
Sentence Learning
AI-Discovered Peptide BRP Shows Potential for Obesity Treatment with Reduced Side Effects
Introduction
Researchers at Stanford Medicine have identified a naturally occurring molecule, called BRP, which suppresses appetite by acting directly on the brain''s hypothalamus. The discovery, made possible by an artificial intelligence tool, may lead to new obesity treatments that avoid the gastrointestinal side effects associated with current GLP-1 receptor agonist drugs such as Ozempic, Wegovy, and Mounjaro.
Main Body
The molecule BRP is a 12-amino-acid peptide that was found using a custom AI system called Peptide Predictor. This tool scanned about 20,000 human genes and identified 2,683 candidate hormone-like peptides. From these, the Stanford team selected around 100 for testing. BRP proved to be the most effective at reducing weight in obese mice. The mice that received daily injections lost weight, while untreated control mice gained weight. Katrin Svensson, the senior author of the study, has co-founded a company to begin human clinical trials soon. Current weight-loss injections copy the hormone GLP-1, which acts on multiple body systems to suppress appetite. However, their main mechanism involves the hindbrain, which creates feelings of fullness. In many patients, this leads to nausea, vomiting, diarrhea, abdominal pain, and constipation. Giles Yeo, professor of molecular neuroendocrinology at the UK Medical Research Council''s Metabolic Diseases Unit, explained that the hindbrain causes physical effects such as uncomfortable fullness, whereas the hypothalamus works as a hunger sensor that detects when the body needs energy. BRP appears to act only on the hypothalamus, potentially reducing appetite without causing the unpleasant fullness that leads to nausea. Furthermore, animal trials showed that BRP promoted fat loss without muscle loss, a side effect sometimes seen with GLP-1 mimics. Randy J. Seeley, professor of surgery at the University of Michigan, commented positively on the scale of the peptide screening but warned that success in animal models does not guarantee that the drug will work or be safe in humans. He noted that obesity is a chronic condition requiring long-term treatment, so any new drug must be very safe for prolonged use. GLP-1-based drugs, which are modified versions of natural hormones engineered to last longer in the body, also offer cardiovascular benefits beyond weight loss. BRP could similarly be changed to have extended activity. Yeo emphasized that additional treatment options are very important given the global obesity crisis, with about one billion people affected and obesity now causing more deaths than famine. He stated that having a variety of tools increases the chance that patients will find a sustainable treatment plan and maintain weight loss.
Conclusion
The discovery of BRP could be an important step forward in obesity treatment, offering a mechanism that may avoid the nausea associated with current GLP-1 agonists. However, its clinical usefulness depends on successful human trials and long-term safety assessments. Even if approved, BRP is expected to complement rather than replace existing treatments, as GLP-1 drugs provide additional health benefits. The use of AI to identify new peptides is a methodological innovation that could speed up future drug development.
Vocabulary Learning
Sentence Learning
AI-Discovered Peptide BRP Shows Potential for Obesity Treatment with Reduced Side Effects
Introduction
Researchers at Stanford Medicine have identified a naturally occurring molecule, designated BRP, which suppresses appetite by acting directly on the brain''s hypothalamus. The discovery, facilitated by an artificial intelligence tool, may lead to new obesity treatments that avoid the gastrointestinal side effects associated with current GLP-1 receptor agonist drugs such as Ozempic, Wegovy, and Mounjaro.
Main Body
The molecule BRP is a 12-amino-acid peptide that was isolated using a custom AI system called Peptide Predictor. This tool scanned approximately 20,000 human genes and identified 2,683 candidate hormone-like peptides, from which the Stanford team selected about 100 for testing. BRP emerged as the most effective in reducing weight in obese mice, which lost weight after daily injections while untreated controls gained weight. Katrin Svensson, the senior author of the study, has co-founded a company to initiate human clinical trials in the near future. Current weight-loss injections mimic the hormone GLP-1, which acts on multiple body systems to suppress appetite. However, their primary mechanism involves the hindbrain, which generates sensations of fullness and, in many patients, leads to nausea, vomiting, diarrhea, abdominal pain, and constipation. Giles Yeo, professor of molecular neuroendocrinology at the UK Medical Research Council''s Metabolic Diseases Unit, explained that the hindbrain targets visceral effects such as uncomfortable fullness, whereas the hypothalamus functions as a hunger sensor that detects energy deficit. BRP appears to act exclusively on the hypothalamus, potentially reducing appetite without inducing the unpleasant fullness that causes nausea. Additionally, animal trials indicated that BRP promoted fat loss without muscle loss, a side effect sometimes observed with GLP-1 mimics. Randy J. Seeley, professor of surgery at the University of Michigan, praised the scale of the peptide screening but cautioned that success in animal models does not guarantee efficacy or safety in humans. He noted that obesity is a chronic condition requiring long-term treatment, so any new drug must demonstrate a high safety profile for prolonged use. GLP-1-based drugs, which are modified versions of natural hormones engineered to last longer in the body, also offer cardiovascular benefits beyond weight loss. BRP could similarly be modified for extended activity. Yeo emphasized that additional treatment options are critical given the global obesity crisis, with approximately one billion people affected and obesity now causing more deaths than famine. He stated that having a variety of tools increases the likelihood that patients will find a sustainable regimen and maintain weight loss.
Conclusion
The discovery of BRP represents a potential advancement in obesity pharmacotherapy, offering a mechanism that may circumvent the nausea associated with current GLP-1 agonists. However, its clinical utility remains contingent on successful human trials and long-term safety assessments. Even if approved, BRP is expected to complement rather than replace existing treatments, as GLP-1 drugs provide additional health benefits. The use of AI to identify novel peptides marks a methodological innovation that could accelerate future drug development.